Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis
Abstract
BACKGROUND: Interferon (IFN) beta is a safe and efficient drug for treating multiple sclerosis (MS). It is widely accepted that previously depressed patients may get worse when using IFN-beta. There are few reports on the association of IFN-beta and severe depression among patients without previous psychiatric history. METHODS: Discussion of a case of a patient with MS who developed severe depression and attempted suicide while using IFN-beta encouraged us to review the subject. A group of neurologists in Brazil retrospectively gathered together their similar cases for the present paper. RESULTS: The present paper reports on 11 cases of severe depression with suicide attempts or ideation among patients with MS who were using IFN-beta. These patients had no previous history of any psychiatric disease. Nine patients developed the symptoms over a relatively short period (4 months, on average). Two patients developed severe depression after more than 1 year of treatment with IFN-beta. Phobic, aggressive, behavioral, psychotic, and manic symptoms also were observed in these patients, thus suggesting the existence of a complex mood-behavior disorder associated with this drug. Interferon beta withdrawal led to complete remission of symptoms. The Naranjo algorithm established a highly probable association between IFN-beta and this adverse reaction in these patients. CONCLUSIONS: Although uncommon, severe depression with suicide ideation or attempts may be observed during treatment of MS with IFN-beta. This association should not discourage the use of this drug, but physicians need to be aware of this possible adverse event from IFN-beta.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Increased suicidal ideation was observed in patients receiving pro-inflammatory cytokines for the treatment of multiple sclerosis.
“and in patients receiving pro-inflammatory cytokines for the treatment of multiple sclerosis.[19]”
From SUICIDAL IDEATION IS ASSOCIATED WITH ELEVATED INFLAMMATION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: Research Article: Suicidal Ideation and Inflammation (2013) · cites this paper as [19]
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914 · see citing works
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969 · see citing works
Raison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630 · see citing works
Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management
Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00002 · Cited by 483 · see citing works
Multiple sclerosis beyond EDSS: depression and fatigue.
Ziemssen, T. (2009) · Journal of Neurological Sciences · doi:10.1016/s0022-510x(09)70011-5 · Cited by 168 · see citing works
Interferon in relapsing-remitting multiple sclerosis
Rice, G. P., Incorvaia, B., Munari, L., Ebers, G. C., Polman, C. H., D’Amico, R., Parmelli, E., & Filippini, G. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002002 · Cited by 144 · see citing works
Neuropsychiatric disorders related to interferon and interleukins treatment
Myint, A. M., Schwarz, M. J., Steinbusch, H. W. M., & Leonard, B. E. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9114-5 · Cited by 116 · see citing works
Multiple Sclerosis, interferon beta-1b and depression
Feinstein, A., O’Connor, P., & Feinstein, K. (2002) · Journal of Neurology · doi:10.1007/s00415-002-0725-0 · Cited by 103 · see citing works
Psychiatric side effects of interferon-β in multiple sclerosis
Goëb, J.-L., EVEN, C., Nicolas, G., Gohier, B., Dubas, F., & Garré, J.-B. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2005.09.013 · Cited by 95 · see citing works
Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study
Fermo, S. L., Barone, R. M. E., Patti, F., Laisa, P., Cavallaro, T. L., Nicoletti, A. S. Q., & Zappia, M. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510365157 · Cited by 79 · see citing works
Major depression during interferon-α treatment: vulnerability and prevention
Lotrich, F. E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.4/felotrich · Cited by 71 · see citing works
Course of Depression During the Initiation of Interferon Beta-1a Treatment for Multiple Sclerosis
Mohr, D. C., Likosky, W., Dwyer, P., Wende, J. V. D., Boudewyn, A. C., & Goodkin, D. (1999) · Archives of Neurology · doi:10.1001/archneur.56.10.1263 · Cited by 68 · see citing works
Interferon-β1afor the treatment of multiple sclerosis
Clerico, M., Contessa, G., & Durelli, L. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.4.535 · Cited by 64 · see citing works
Managing Depression during Hepatitis C Treatment
Sockalingam, S., & Abbey, S. E. (2009) · The Canadian Journal of Psychiatry · doi:10.1177/070674370905400906 · Cited by 60 · see citing works
Erim, Y., Tagay, S., Beckmann, M., Bein, S., Cicinnati, V., Beckebaum, S., Senf, W., & Schlaak, J. F. (2010) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2009.08.002 · Cited by 48 · see citing works
Goëb, J.-L., Cailleau, A., Lainé, P., Etcharry‐Bouyx, F., Maugin, D., Duverger, P., Gohier, B., Rannou-Dubas, K., Dubas, F., & Garré, J.-B. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200301000-00002 · Cited by 41 · see citing works
Assessing the Role of Drugs in Suicidal Ideation and Suicidality
Reith, D. M., & Edmonds, L. K. (2007) · CNS Drugs · doi:10.2165/00023210-200721060-00003 · Cited by 41 · see citing works
Interferon beta-1a-induced depression and suicidal ideation in multiple sclerosis.
Lana-Peixoto, M., Teixeira, A., & Haase, V. (2002) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2002000500007 · Cited by 34 · see citing works
Long-term emotional state of multiple sclerosis patients treated with interferon beta
Porcel, J., Río, J., Sánchez-Betancourt, A., Arévalo, M. J., Tintoré, M., Téllez, N., Borrás, C., Nos, C., & Montalbán, X. (2006) · Multiple Sclerosis Journal · doi:10.1177/1352458506070748 · Cited by 30 · see citing works
High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis
Hartung, H. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802677882 · Cited by 21 · see citing works
Psychiatric disorders in multiple sclerosis patients
Fazzito, M. M., Jordy, S. S., & Tilbery, C. P. (2009) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2009000400017 · Cited by 20 · see citing works
Carroll, W. M. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458509105426 · Cited by 18 · see citing works
Dépression et sclérose en plaques
Lebrun‐Frénay, C., & Cohen, M. (2009) · Revue Neurologique · doi:10.1016/s0035-3787(09)72128-9 · Cited by 14 · see citing works
Boyко, A. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003702361 · Cited by 11 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Connecting inflammation with glutamate agonism in suicidality
Erhardt, S., Lim, C. K., Linderholm, K. R., Janelidze, S., Lindqvist, D., Samuelsson, M., Lundberg, K., Postolache, T. T., Träskman-Bendz, L., Guillemin, G. J., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.248 · Cited by 345 · see citing works
Toward a Biosignature for Suicide
Oquendo, M. A., Sullivan, G. M., Sudol, K., Baca-Garcia, E., Stanley, B. H., Sublette, M. E., & Mann, J. J. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14020194 · Cited by 299 · see citing works
Bay-Richter, C., Linderholm, K. R., Lim, C. K., Samuelsson, M., Träskman-Bendz, L., Guillemin, G. J., Erhardt, S., & Brundin, L. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.07.012 · Cited by 304 · see citing works
Role of Inflammation in Suicide: From Mechanisms to Treatment
Brundin, L., Bryleva, E. Y., & Thirtamara Rajamani, K. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.116 · Cited by 257 · see citing works
“In a subset of MS patients with no history of psychiatric illness, treatment with IFN-γ worsens depressive symptoms and induces suicidal ideation or attempts (Benros et al , 2011; Chwastiak et al , 2002; Fragoso et al , 2010).”
Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder
Sublette, M. E., Galfalvy, H. C., Fuchs, D., Lapidus, M., Grunebaum, M. F., Oquendo, M. A., John Mann, J., & Postolache, T. T. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.05.002 · Cited by 250 · see citing works
O'Donovan, A., Rush, G., Hoatam, G., Hughes, B. M., McCrohan, A., Kelleher, C., O'Farrelly, C., & Malone, K. M. (2013) · Depression and Anxiety · doi:10.1002/da.22087 · Cited by 210 · see citing works
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
Filippini, G., Giovane, C. D., Vacchi, L., D’Amico, R., Pietrantonj, C. D., Beecher, D., & Salanti, G. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008933.pub2 · Cited by 186 · see citing works
Serafini, G., Parisi, V. M., Aguglia, A., Amerio, A., Sampogna, G., Fiorillo, A., Pompili, M., & Amore, M. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17072393 · Cited by 172 · see citing works
The role of inflammation in suicidal behaviour
Brundin, L., Erhardt, S., Bryleva, E. Y., Achtyes, E. D., & Postolache, T. T. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12458 · Cited by 174 · see citing works
Suicide risk in multiple sclerosis: a systematic review of current literature
Pompili, M., Forte, A., Palermo, M., Stefani, H., Lamis, D. A., Serafini, G., Amore, M., & Girardi, P. (2012) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2012.09.011 · Cited by 163 · see citing works
Neuroinflammation in suicide: Toward a comprehensive model
Courtet, P., Giner, L., Seneque, M., Guillaume, S., Olie, E., & Ducasse, D. (2016) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1054879 · Cited by 146 · see citing works
Colasanti, A., Guo, Q., Giannetti, P., Wall, M. B., Newbould, R. D., Bishop, C., Onega, M., Nicholas, R. S., Ciccarelli, O., Muraro, P. A., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.11.022 · Cited by 145 · see citing works
Blunted HPA axis activity prior to suicide attempt and increased inflammation in attempters
Melhem, N. M., Munroe, S., Marsland, A., Gray, K., Brent, D., Porta, G., Douaihy, A., Laudenslager, M. L., DePietro, F., Diler, R., et al. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.01.001 · Cited by 124 · see citing works
Ketamine as a Potential Treatment for Suicidal Ideation: A Systematic Review of the Literature
Reinstatler, L., & Youssef, N. A. (2015) · Drugs in R&D · doi:10.1007/s40268-015-0081-0 · Cited by 120 · see citing works
A meta-analysis of cytokines in suicidal behavior
Ducasse, D., Olié, E., Guillaume, S., Artéro, S., & Courtet, P. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.02.004 · Cited by 119 · see citing works
Neurobiological Basis of Increased Risk for Suicidal Behaviour
Wisłowska-Stanek, A., Kołosowska, K., & Maciejak, P. (2021) · Cells · doi:10.3390/cells10102519 · Cited by 115 · see citing works
Bolton, J. M., Walld, R., Chateau, D. G., Finlayson, G., & Sareen, J. (2014) · Psychological Medicine · doi:10.1017/s0033291714001639 · Cited by 110 · see citing works
Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis
Zhang, T., Tremlett, H. L., Leung, S., Zhu, F., Kingwell, E., Fisk, J. D., Bhan, V., Campbell, T. L., Stadnyk, K., Yu, B. N., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002543 · Cited by 107 · see citing works
Increased CRP levels may be a trait marker of suicidal attempt
Courtet, P., Jaussent, I., Genty, C., Dupuy, A. M., Guillaume, S., Ducasse, D., & Olié, E. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.05.003 · Cited by 96 · see citing works
Inflammation and lithium: clues to mechanisms contributing to suicide-linked traits
Beurel, E., & Jope, R. S. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.129 · Cited by 92 · see citing works
Psychiatric manifestations in cerebrotendinous xanthomatosis
Fraidakis, M. J. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.76 · Cited by 91 · see citing works
Kallaur, A. P., Lopes, J. M., Oliveira, S. R., Simão, A. N. C., Reiche, E. M. V., de Almeida, E. R. D., Morimoto, H. K., de Pereira, W. L. C. J., Alfieri, D. F., Borelli, S. D., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9443-4 · Cited by 82 · see citing works
Targeting NOX enzymes in the central nervous system: therapeutic opportunities
Sorce, S., Krause, K., & Jaquet, V. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1014-5 · Cited by 78 · see citing works
Miola, A., Porto, V. D., Tadmor, T., Croatto, G., Scocco, P., Manchia, M., Carvalho, A. F., Maes, M. H. J., Vieta, E., Sambataro, F., et al. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13351 · Cited by 74 · see citing works
Taylor, K. L., Hadgkiss, E. J., Jelinek, G. A., Weiland, T. J., Pereira, N. G., Marck, C. H., & van der Meer, D. M. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0327-3 · Cited by 70 · see citing works
Chang, C.-C., Tzeng, N.-S., Kao, Y.-C., Yeh, C.-B., & Chang, H.-A. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.08.076 · Cited by 65 · see citing works
A systematic review of validated suicide outcome classification in observational studies
Swain, R. S., Taylor, L. G., Braver, E. R., Liu, W., Pinheiro, S. P., & Mosholder, A. D. (2019) · International Journal of Epidemiology · doi:10.1093/ije/dyz038 · Cited by 62 · see citing works
Psychiatric symptoms in patients with multiple sclerosis
Sarísoy, G., Terzi, M., Gümüş, K., & Pazvantoğlu, O. (2012) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2012.10.011 · Cited by 53 · see citing works
Interferon-α (IFNα) neurotoxicity
Fritz-French, C., & Tyor, W. R. (2012) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2012.01.001 · Cited by 46 · see citing works
The varieties of psychosis in multiple sclerosis: A systematic review of cases
Camara-Lemarroy, C. R., Ibarra-Yruegas, B. E., Rodríguez‐Gutiérrez, R., Morales, I. B., Ionete, C., & Riskind, P. N. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.12.012 · Cited by 43 · see citing works
Type I IFN-mediated regulation of IL-1 production in inflammatory disorders
Ludigs, K., Parfenov, V., Pasquier, R. D., & Guarda, G. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0989-2 · Cited by 37 · see citing works
Depression and anxiety in multiple sclerosis. Review of a fatal combination
Jellinger, K. A. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-024-02792-0 · Cited by 41 · see citing works
Iacovides, A., & Andreoulakis, E. (2011) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328347341d · Cited by 35 · see citing works
Choi, K. W., Jang, E. H., Kim, A. Y., Kim, H., Park, M. J., Byun, S., D, M. F. M., Mischoulon, D., Papakostas, G. I., Yu, H. Y., et al. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.12.011 · Cited by 35 · see citing works
Immunoregulation and antidepressant effect of ketamine
Zhang, N., Yao, L., Wang, P., & Liu, Z. (2021) · Translational Neuroscience · doi:10.1515/tnsci-2020-0167 · Cited by 35 · see citing works
Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches
Jurdi, R. K. A., Swann, A. C., & Mathew, S. J. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0614-9 · Cited by 30 · see citing works
Martínez-Botía, P., Velasco, A., Rolle, V., Jiménez-Trevino, L., De la Fuente-Tomás, L., Bernardo, Á., Arias, T., Muñoz-Turrillas, M. D. C., García-Alvarez, L., González-Blanco, L., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.06.006 · Cited by 27 · see citing works
Recommendations on diagnosis and treatment of depression in patients with multiple sclerosis
Fragoso, Y. D., Adoni, T., Anacleto, A., da Gama, P. D., Goncalves, M. V. M., Matta, A. P. D. C., & Parolin, M. K. F. (2014) · Practical Neurology · doi:10.1136/practneurol-2013-000735 · Cited by 25 · see citing works
The Neuroscience of Suicidal Behavior
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205 · Cited by 22 · see citing works
Kouchaki, E., Namdari, M., Khajeali, N., Etesam, F., & Asgarian, F. S. (2020) · Social Work in Public Health · doi:10.1080/19371918.2020.1810839 · Cited by 22 · see citing works
Römer, T., Franzen, S., Kravets, H., Farrag, A., Makowska, A. M., Christiansen, H., Eble, M. J., Timmermann, B., Staatz, G., Mottaghy, F. M., et al. (2022) · Cancers · doi:10.3390/cancers14051261 · Cited by 22 · see citing works
Bay-Richter, C., Janelidze, S., Sauro, A., Bucala, R., Lipton, J. W., Deierborg, T., & Brundin, L. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0387-4 · Cited by 22 · see citing works
Therapeutic spectrum of interferon‐β in ischemic stroke
Wanve, M., Kaur, H., Sarmah, D., Saraf, J., Pravalika, K., Vats, K., Kalia, K., Borah, A., Yavagal, D. R., Dave, K. R., et al. (2018) · Journal of Neuroscience Research · doi:10.1002/jnr.24333 · Cited by 22 · see citing works
RNA editing blood biomarkers for predicting mood alterations in HCV patients
Salvetat, N., van der Laan, S., Vire, B., Chimienti, F., Cléophax, S., Bronowicki, J., Doffoël, M., Bourlière, M., Schwan, R., Lang, J.-P., et al. (2019) · Journal of NeuroVirology · doi:10.1007/s13365-019-00772-9 · Cited by 20 · see citing works
The emotional disorders associated with multiple sclerosis.
Raimo, S., Santangelo, G., & Trojano, L. (2021) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-822290-4.00009-8 · Cited by 19 · see citing works
Broadley, S., Barnett, M. H., Boggild, M., Brew, B. J., Butzkueven, H., Heard, R. N., Hodgkinson, S. J., Kermode, A. G., Lechner‐Scott, J., Macdonell, R. A. L., et al. (2014) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.01.016 · Cited by 19 · see citing works
Andronis, C., Silva, J. P., Lekka, E., Virvilis, V., Carmo, H., Bampali, K., Ernst, M. C., Hu, Y., Loryan, I., Richard, J., et al. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02788-1 · Cited by 18 · see citing works
Donegan, J. J., & Nemeroff, C. B. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-7376-5_17 · Cited by 18 · see citing works
Literature systematic review on the ophthalmological side effects of interferons
Fragoso, Y. D., Paggiaro, M. S. S., Mastromauro, R., Jacondino, G. D. S., & Wilson, H. M. (2011) · Arquivos Brasileiros de Oftalmologia · doi:10.1590/s0004-27492011000400017 · Cited by 17 · see citing works
Olianas, M. C., Dedoni, S., & Onali, P. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13570 · Cited by 17 · see citing works
Siracusano, A., Niolu, C., Sacchetti, L., & Ribolsi, M. (2012) · Springer eBooks · doi:10.1007/978-88-470-2676-6_11 · Cited by 14 · see citing works
Assessing risks of multiple sclerosis therapies
Parfenov, V., Schluep, M., & Pasquier, R. D. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.06.013 · Cited by 13 · see citing works
Mehta, A., Ratre, Y. K., Sharma, K., Soni, V. K., Tiwari, A. K., Singh, R. P., Dwivedi, M. K., Chandra, V., Prajapati, S. K., Shukla, D., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.769884 · Cited by 11 · see citing works
The Main Determinants for Suicidal Ideation in a Romanian Cohort of Multiple Sclerosis Patients
Romaniuc, A., Bălașa, R., Ştirbu, N., Maier, S., Andone, S. R., Bajkó, Z., Bărcuţean, L., Voidăzan, S. T., & Moțățăianu, A. (2020) · Behavioural Neurology · doi:10.1155/2020/2594702 · Cited by 10 · see citing works
Tan, L. S. Y., Francis, H., & Lim, C. K. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100201 · Cited by 11 · see citing works
Neuroimmune, clinical and treatment challenges in multiple sclerosis-related psychoses
Vesić, K., Gavrilović, A., Mijailović, N. R., & Borovčanin, M. (2023) · World Journal of Psychiatry · doi:10.5498/wjp.v13.i4.161 · Cited by 9 · see citing works
Gonda, X., Serafini, G., & Döme, P. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13071078 · Cited by 9 · see citing works
Leonavičius, R., Adomaitienė, V., & Leskauskas, D. (2011) · Open Medicine · doi:10.2478/s11536-011-0059-4 · Cited by 6 · see citing works
Faustmann, T. J., Wawrzyniak, M., Faustmann, P. M., Corvace, F., & Ismail, F. S. (2023) · Brain Sciences · doi:10.3390/brainsci13030493 · Cited by 7 · see citing works
Emerging RNA editing biomarkers will foster drug development
van der Laan, S., Salvetat, N., Weissmann, D., & Molina, F. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.017 · Cited by 7 · see citing works
Psychische Störungen bei somatischen Krankheiten
Kapfhammer, H. P. (2011) · Springer eBooks · doi:10.1007/978-3-642-03637-8_76 · Cited by 7 · see citing works
Comprehensive view of suicide: A neuro-immune-endocrine approach
Ponce-Regalado, M. D., Becerril‐Villanueva, E., Maldonado-García, J. L., Moreno-Lafont, M. C., Martínez-Ramírez, G., Jacinto-Gutiérrez, S., Arreola, R., Sánchez-Huerta, K., de Oca, A. C.-M., López-Martínez, K. M., et al. (2025) · World Journal of Psychiatry · doi:10.5498/wjp.v15.i2.98484 · Cited by 7 · see citing works
Psychische Störungen bei somatischen Krankheiten
Kapfhammer, H. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_88 · Cited by 6 · see citing works
Ariapooran, S., Rajabi, M., & Goodarzi, A. (2016) · Asian Social Science · doi:10.5539/ass.v12n8p192 · Cited by 6 · see citing works
The Association Between Physical Illness/Medical Conditions and Suicide Risk
Pompili, M., Forte, A. M., Berman, A. L., & Lamis, D. A. (2016) · Wiley eBooks · doi:10.1002/9781118903223.ch8 · Cited by 6 · see citing works
García‐Gutiérrez, M. S., Caparrós, E., Torregrosa, A. B., Martínez‐López, S., Gasparyan, A., Giner, S., & Manzanares, J. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00634 · Cited by 5 · see citing works
Kapfhammer, H. (2014) · Neuropsychiatrie · doi:10.1007/s40211-014-0105-y · Cited by 4 · see citing works
Liu, W., Zheng, H., Wen, X., Liu, L., Yang, Y., & Zhong, H. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1491555 · Cited by 4 · see citing works
Depressies bij multiple sclerose
Arts, N. J. M. (2013) · Tijdschrift voor Neuropsychiatrie en Gedragsneurologie · doi:10.1007/s40533-013-0003-9 · Cited by 4 · see citing works
Sriwastava, S., Beard, K., Amatya, S., Shrestha, K., Jaiswal, S., & Lisak, R. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95343-6.00014-5 · Cited by 3 · see citing works
Neurodegenerative disease and suicide
Calero, M. G. R., & Galiano, A. B. J. (2021) · Revista Científica de la Sociedad de Enfermería Neurológica (English ed ) · doi:10.1016/j.sedeng.2021.02.003 · Cited by 3 · see citing works
Inflammation and Suicidal Behavior
Postolache, T. T., Manalai, P., Brenner, L. A., & Brundin, L. (2015) · Advances in biological psychiatry · doi:10.1159/000434746 · Cited by 3 · see citing works
Assessing Psychiatric Adverse Effects during Clinical Drug Development
Rudorfer, M. V., & Hillefors, M. (2012) · Pharmaceutical Medicine · doi:10.1007/bf03262382 · Cited by 3 · see citing works
Biological basis of suicidal behavior
Зинчук, М. С., Guekht, A. B., Gulyaeva, N. V., Аведисова, А. С., Akzhigitov, R. G., & Гришкина, М. Н. (2016) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20161168194-101 · Cited by 4 · see citing works
Orsolini, L., Longo, G., Cavallo, L., & Volpe, U. (2025) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2025.107612 · Cited by 2 · see citing works
Understanding Psychosis in a Veteran With a History of Combat and Multiple Sclerosis.
Lee, A., & Nathan, K. (2019) · PubMed Central · Cited by 2 · see citing works
Stress, Vulnerability, and Suicide
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.003 · Cited by 2 · see citing works
Sahakyan, A., & Mavelyan, H. M. (2022) · Neurology India · doi:10.4103/0028-3886.349619 · Cited by 2 · see citing works
Psychische Störungen bei somatischen Krankheiten
Kapfhammer, H. (2015) · Springer eBooks · doi:10.1007/978-3-642-45028-0_88-1 · Cited by 2 · see citing works
Psychiatric Symptoms and Disorders in Multiple Sclerosis: Review
Sönmez, İ., Mut, S. E., & BOZKURT, A. (2016) · Turkiye Klinikleri Journal of Neurology · doi:10.5336/neuro.2016-51118 · Cited by 2 · see citing works
Tauil, C. B., von Glehn, F., Delgado-Rodrigues, R. N., GOMES, J. R. A., Brandão, C. O., dos Santos, L. M. B., & dos Santos‐Neto, L. L. (2019) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20190049 · Cited by 2 · see citing works
Neuroinflammation in depression
Dobos, N. (2014) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 2 · see citing works
Perspectives on the Neurobiology of Youth Suicide Within an RDoC Framework
Liu, R. T., Kudinova, A. Y., Tsypes, A., & Cheek, S. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-82465-5_4 · Cited by 1 · see citing works
Christian, L. M., Andridge, R., Peng, J., Kasibhatla, N. P., McDade, T. W., Blevins, T. R., Cole, S. W., Manning, W. D., & Dush, C. M. K. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106202 · Cited by 1 · see citing works
Ducasse, D., Girod, C., & Courtet, P. (2016) · Springer eBooks · doi:10.1007/978-3-319-26282-6_10 · Cited by 1 · see citing works
Lithium: The Key Antisuicide Agent
Bellivier, F., & Guillaume, S. (2016) · Springer eBooks · doi:10.1007/978-3-319-26282-6_25 · Cited by 1 · see citing works
Enfermedad neurodegenerativa y suicidio
Calero, M. G. R., & Galiano, A. B. J. (2021) · Revista Científica de la Sociedad Española de Enfermería Neurológica · doi:10.1016/j.sedene.2021.02.003 · Cited by 1 · see citing works
Is psyche-soma dichotomy still clinically appropriate?
Torta, R., Botto, R., Giorgi, V., & Sarzi‐Puttini, P. (2023) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/x3pyfb · Cited by 1 · see citing works
Interferon-β1b in der Multiple-Sklerose-Therapie
Hartung, H. ‐., Haas, J., Meergans, M., Tracik, F. M., & Ortler, S. (2013) · Der Nervenarzt · doi:10.1007/s00115-013-3781-0 · Cited by 1 · see citing works
The risk of depression in chronic obstructive pulmonary disease
Pietras, T., Witusik, A., & Kuna, P. (2011) · Cited by 1 · see citing works
Reisi‐Vanani, V., & Keihani, M. (2022) · Minerva Psychiatry · doi:10.23736/s2724-6612.21.02199-0 · Cited by 1 · see citing works
Reacciones adversas psiquiátricas
Giménez, A. (2011) · Hispana
Verträglichkeit von Interferonen
Hellwig, K. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1766-8_13
Ionenkanalmodulation durch Interferon in Layer V Pyramidenneuronen des somatosensorischen Cortex
Stadler, K. (2012) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-7605
Effect of systemic interferon-α on the lacrimal gland and cornea of mice
El‐Tahawy, N. F. G., & Rifaai, R. A. (2015) · The Egyptian Journal of Histology · doi:10.1097/01.ehx.0000464732.18468.11
Glatiramer acetate in clinically isolated syndrome and its early onset of effect
Piťha, J. (2018) · Neurologie pro praxi · doi:10.36290/neu.2019.011
What Is Suicidal Behavior, and Can It Be Prevented?
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.002
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.008
I Predict, Therefore I Cannot Be
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.009
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.010
- Authors
- Fragoso, Y. D., Frota, E. R. C., Lopes, J. S., Noal, J. S., Giacomo, M. C., Gomes, S., Gonçalves, M. V. M., da Gama, P. D., & Finkelsztejn, A.
- Affiliations
- Beneficência Portuguesa de São Paulo (BR)
- Hospital de Clínicas de Porto Alegre (BR)
- Corresponding author
- Finkelsztejn, Alessandro
- Venue
- Clinical Neuropharmacology
- Published
- 2010-11
- Volume
- 33
- Issue
- 6
- Pages
- 312-316
- ISSN
- 0362-5664 (ISSN-L)
- OpenAlex
- W2018025671
- Cited by
- 116
- References
- 24
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 3 · 2023: 7 · 2022: 3 · 2021: 10 · 2020: 6 · 2019: 4 · 2018: 18 · 2017: 4 · 2016: 10 · 2015: 12 · 2014: 9 · 2013: 7 · 2012: 9
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Neuropharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- interferon-beta, multiple sclerosis, severe depression, suicide attempts, suicidal ideation, adverse drug reactions, interferon withdrawal, Naranjo algorithm, psychiatric adverse effects
- MeSH terms
- Adult, Brazil, Depressive Disorder, Female, Humans, Interferon Type I, Male, Middle Aged, Multiple Sclerosis, Recombinant Proteins, Suicide, Attempted, Prevalence, Treatment Outcome, Drug Monitoring, Mood Disorders, Young Adult, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
